All Posts

At Fletcher, we’ve spent over 35 years helping companies win with deep, tailored research. But the world has changed. Teams are moving faster. Budgets are tighter. The appetite for drawn-out projects is shrinking...

We recently marked Rare Disease Day, a vital moment for the community. For those impacted by rare pathologies, the journey is often defined by a grueling "diagnostic odyssey," complex symptom management, and the constant hurdle of managed care coverage. For many, cell and gene therapy (CGT) represents the ultimate beacon of hope—offering not just chronic disease management, but the potential for curative outcomes.

Let’s be honest: Most battlecards are digital paperweights. They are built with good intentions, filed into a content system, and promptly ignored. But there’s a new twist to this old problem. When a high-stakes deal gets intense, reps aren't just falling back on instinct, they are turning to AI.